HR+ Breast Cancer Clinical Trials
0 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 1
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
HR+ Breast Cancer
NiKang Therapeutics, Inc.205 enrolled14 locationsNCT07029399
Recruiting
Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
HR+ Breast Cancer
Hunan Cancer Hospital80 enrolled1 locationNCT06734533